key: cord-0741462-315gn7lc
authors: Bachmann, Friederike; Budde, Klemens; Suttorp, Norbert; Lingscheid, Tilman; Stegemann, Miriam Songa; Osmanodja, Bilgin; Schrezenmeier, Eva; Duettmann, Wiebke; Weber, Ulrike; Naik, Marcel; Lehner, Lukas Johannes; Kahl, Andreas; Duerr, Michael; Eckardt, Kai-Uwe; Waiser, Johannes; Choi, Mira; Halleck, Fabian
title: Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients
date: 2022-03-31
journal: Transpl Int
DOI: 10.3389/ti.2022.10109
sha: b5a29c821e1db3fddc1f9dc90c60a3eacf8d84a1
doc_id: 741462
cord_uid: 315gn7lc

Background: Antiviral drugs have shown little impact in patient infected with acute respiratory coronavirus 2 (SARS-CoV-2). Especially for immunocompromised persons positive for SARS-CoV-2, novel treatments are warranted. Recently, the U.S. FDA has granted an emergency use authorization (EUA) to two monoclonal antibodies (mAb) targeting the viral spike protein: bamlanivimab and casivirimab and imdevimab. As per the EUA, all SARS-CoV-2 positive organ transplant recipients can receive mAb treatment. Patients and methods: We queried our center’s transplant registry to identify SARS-CoV-2 infected recipients treated with single doses of either Bamlanivimab or casivirimab/imdevimab up to May 31, 2021. We analyzed clinical outcomes, renal function and virus-specific antibodies. The co-primary endpoints were hospitalization due to COVID-19 and SARS-CoV-2 RT-PCR negativity. Results: Thirteen patients at a median interval of 55 (IQR, 26-110) months from transplant were treated: 8 with bamlanivimab and 5 with casivirimab/imdevimab. In all, 4/13 (31%) patients were hospitalized at some time, while 11/13 (85%) achieved PCR negativity. 2/4 hospitalized patients received mAb as rescue treatment. Overall mortality was 23%, with one death attributable to transplant-associated lymphoma. All six patients infected with the B 1.1.7 variant were alive at last contact. Conclusion: mAb treatment appears effective when administered early to SARS-CoV-2-infected transplant recipients.

BACKGROUND Until now, antiviral drugs have largely failed to improve the natural course of coronavirus disease 19 (COVID-19) (1). In fact, mainly dexamethasone had positive effects on patients severely affected by SARS-CoV-2 (2, 3) . Therefore, antibody treatments (4, 5) attracted strong interest prior to the availability of vaccines in order to ameliorate disease severity in subjects with proven infection. In addition to convalescent plasma (6) , also monoclonal and "off-the-shelf" preparations of neutralizing intravenous immunoglobulins may be effective in fighting SARS-CoV-2 infection (7) . Convalescent plasma might positively impact intensive care unit (ICU) admission and mortality rates (6) . However, these preparations are difficult to standardize and a drug containing high amounts of a well-defined epitope-specific antibody might be superior and exert more reliable efficacy. In fact, two compounds have been granted an emergency use authorization (EUA) by the U.S. FDA for mild to moderate COVID-19 since November 2020 (8, 9) . In Germany both compounds are provided for unlicensed use since January 2021 due to pending approval in Europe.

Bamlanivimab, one of these two compounds, constitutes a neutralizing IgG1 monoclonal antibody (mAb) binding to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 (9) . Bamlanivimab was shown to accelerate elimination of SARS-CoV-2 and, more importantly, reduced probability of emergency department visits by approximately 75% when given to outpatients (7) . Casivirimab and imdevimab are two neutralizing mAbs targeting two different epitopes of the RBD (10) . They are administered together as an "antibody cocktail" with a single dose in subjects who are at high risk for developing severe COVID-19 (5, 11) . The combined phase 1-3 trial met its key efficacy endpoints, in that viral load over time was significantly reduced and medically attended visits were less frequent in patients receiving any dose of casivirimab/ imdevimab (11) .

Chronic kidney disease (CKD) is associated with a higher risk of in-hospital mortality in COVID-19 patients than, for instance, malignancy or cardiac comorbidities, as demonstrated in several large studies (12, 13) . Overall mortality in hospitalized CKD patients was 26% (12) . While many CKD patients are of advanced age with age being another major risk factor for poor outcomes, kidney transplantation constitutes a further risk factor for SARS-CoV-2 infected individuals (14, 15) . Besides immunosuppression, graft function was inversely correlated with COVID-19 disease severity (16) . Because immunosuppression may suppress adequate production of protective antibodies, the use of external antibody preparations may be of higher effectivity in kidney transplant recipients, known to be at high risk for poor outcomes. Until now, experience with neutralizing mAbs in COVID-19 kidney transplant recipients under a defined immunosuppression is very limited. In a recent single-center, retrospective study, bamlanivimab reduced the hospitalization rate in a cohort where approximately 30% of patients were of immunosuppression. Of note, the authors estimated the number needed to treat (in order to prevent one hospitalization) to be 8 (17) . To the best of our knowledge, only one case series from outside the U.S. (18) . has been reported so far.

We queried our electronic patient database "TBase" (19) for the search terms "SARS-CoV-2," "COVID-19" and "bamlanivimab" or "casivirimab" or "imdevimab." Retrieved records were manually reviewed for all patients receiving treatment with mAbs preparation "bamlanivimab" or "casivirimab/ imdevimab" until May 31, 2021. All patients had a minimum follow-up of 14 days after mAb infusion, the last of which was administered on May 22, 2021. According to indication, solid organ transplant (SOT) recipients with a positive SARS-CoV-2 PCR were treated with 700 mg bamlanivimab or 1200 mg casivirimab/imdevimab. The decision to treat was made by a multidisciplinary team consisting of nephrologists, transplant physicians and infectious disease specialists. We collected clinical outcomes, medication history, laboratory results for infection parameters, renal function tests, blood count, and anti-SARS-CoV-2 serum antibodies (IgA and IgG using Euroimmun-ELISA, Lübeck, Germany). All patient samples from the current series were analyzed using NGS-based sequencing of viral genomes as described previously (20) . Methods differed based on viral load in patients' nasal swab. Briefly, libraries were established using the KAPA RNA Hyper Prep kit (high viral load) or a PCR amplicon-based sequencing approach.

Imaging results were used to assess pulmonary infiltration patterns in patients with dyspnea. Telemedicine support, which has been in use for our KTR recipients for about 1 year, was offered to all patients following mAb treatment and comprised symptom-reporting, remote vital sign monitoring, medication intake and chat functioning (21) . The co-primary endpoints were hospitalization due to COVID-19 by day 29 (11) and viral response, respectively. The latter was defined as a SARS-CoV-2 RT-PCR negative (swab) test on day 11 (+/− 2 days) after mAb administration. Sustained response was defined as an ongoing negative PCR negativity at further testing. In contrast to mAb pivotal studies, we used dichotomized PCR test results rather than log reduction of viral load. We additionally defined a composite secondary endpoint which was defined by admission to ICU, any form of ventilation, or death. Disease-specific survival was calculated from first positive SARS-CoV-2 PCR test until death from any cause or last follow-up. Cause of death for deceased patients was attributed to COVID-19 if their last PCR was positive and/or they met criteria for severe COVID-19 at last follow-up and/or they died due to pulmonary involvement of a previously documented SARS-CoV-2 infection.

In total, thirteen organ transplant recipients were identified and included in this report. The median age was 52 (IQR 42-60) years. Baseline demographics are shown in Tables 1, 2 Table 1) . Bamlanivimab was administered to the first eight patients, including all three hospitalized patients. When casivirimab/imdevimab became available at our center, we switched mAb treatment to this compound. Both antibody preparations were well tolerated and we did not observe any infusion-related reactions.

For two of three patients ( Table 2 : patients 12 and 13) who were already hospitalized and had received other treatments, including dexamethasone and convalescent plasma, mAb administration was delivered as a rescue treatment. Therefore, MMF was discontinued and tacrolimus dosage was adjusted to trough levels of 4-6 ng/ml. One of these two patients had refractory PTLD/acute lymphoblastic leukemia with leukemic meningitis. Both patients had acute kidney injury requiring dialysis. They died on day 45 and day 60, respectively, after diagnosis of intractable COVID-19 with virus persistence until death.

Another hospitalized patient ( All remaining 10 patients received mABs during outpatient care with mild symptoms and according to the respective notice of the general ruling by the Federal Ministry of Health (Bundesgesundheitsministerium, BMG). Of note, none of the six carriers of the B.1.1.7 variant needed inpatient care or oxygen supplementation. In addition to standard PCR tests, six patients were tested for the presence of pre-infusion anti-SARS-CoV-2 antibodies. All six were seronegative. As patients were not treated within a prospective study, testing for serum antibodies was performed at discretion of the treating physician in charge.

Therefore, previous infection and preexisting immunity seems unlikely. MMF was reduced by 50% and steroids continued in patients on a steroid maintenance regimen. Despite continued immunosuppression following their organ transplants, 9/10 had an uneventful outpatient course and did not develop severe COVID-19 symptoms requiring hospitalization. SARS-CoV-2 PCR became negative in 6 patients after a median of 22 days (range 18-35). However, one patient with initial viral clearance had symptomatic disease recurrence, and multiple positive PCR tests later on. He was hospitalized on day 21 after diagnosis and died due to COVID-19 associated ARDS in the ICU on day 57 after initial disease onset.

In summary, two out of 11 patients (18%) with early antibody treatment reached the composite endpoint and were admitted to an ICU and required oxygen. With one patient dying due to Covid-19, mortality was still app. 10% in our series. This underscores an ongoing medical need in the severely immunocompromised. In this cohort, time to viral clearance occurred after a median of 20 days, and sustained viral clearance was achieved in 8 patients (73%). Testing for serum antibodies against one subunit of the spike protein (anti-S1 Ig A and IgG) revealed positive results for anti-S1 IgG in all patients after a median of 43 (range, 13-109) days.

Immunocompromised subjects with SARS-CoV-2 infection are prone to an unfavorable course of the disease with a 10-fold increased mortality risk. Pre-emptive administration of monoclonal, virus-neutralizing antibodies that have constant, defined and reproducible characteristics has shown to benefit subjects with mild symptoms from confirmed SARS-CoV-2 infection (7, 10 and 12). We treated 13 consecutive SOT recipients from our center. All but one patient who had received pre-emptive treatment with the mAbs are alive after a follow-up of 40 days. Only one of these 11 patients experienced recurrence of viral infection and eventually died from intractable COVID-19. This patient's fate leads to the speculation that, in light of the half-life of the mAbs (13 days for bamlanivimab and 13-18 days for casivirimab/indevimab) (22) , a single dose might not be appropriate in severely immunocompromised patients or viral immune escape took place due to mAb-monotherapy and insufficient immune-response by the patient. Two severely ill patients received bamlanivimab at a relatively long interval from SARS-CoV-2 infection and died due to complications from underlying disease and refractory COVID-19. Findings for anti-S1 IgG showed positive results for all patients after a median of 43 days from mAb administrations. Especially positive results after app. 80 days from therapeutical antibody infusion suggest "true seroconversion" rather than remaining concentrations of bamlanivimab or casivirimab/imdevimab, respectively. The overall good outcome is particularly remarkable, since in 6 of 13 cases the B.1.1.7 lineage was found to be the infectious agent, which is associated with higher reproducibility and case fatality. All 6 subjects carrying the B.1.1.7 lineage had an uneventful course without need for oxygen or other interventions, suggest efficacy against this variant of concern. Another strength of our study is the fact that prior infection was ruled out for six patients assuming none of these having "natural" immunity. Our study has some limitations: first, the sample size is small. Second, in this exploratory pilot study we did not attempt comparison with a control group not receiving a monoclonal antibody. Third, allocation to any one of the mAbs was by availability and individual decision rather than randomization making any comparison impossible. The dynamic situation of the pandemic is mirrored by incoming virus variants which may escape from treatments established in earlier phases of the pandemic. Of note, early data of a novel compound, sotrovimab, indicate its efficacy also for the Omicron variant (23) . Quickly evolving virus variants may pose a novel threat to communities by questioning established strategies in intervals as short as weeks. For instance, the Omicron type features a magnitude of mutations clustering in the receptor binding motif (RBM) leading to an immune escape not only to the first class of mAbs, but also to covalescent plasma and certain types of vaccinations. Interestingly, the non-RBM targeting second class of mAbs is still effectively neutralizing the Omicron variant as very recently shown by a Swiss group (24) .

Our initial experience with neutralizing mABs for SOT recipients with confirmed SARS-CoV-2 infection shows excellent tolerability and suggests high efficacy including infections with the B.1.1.7 variant. We conclude that in a setting of rescue therapy no clear benefit can be documented, a finding which is in accordance with FDA emergency use authorization while early administration appears efficacious in prevention of severe COVID-19 in heavily immunosuppressed patients with mild symptoms. However, rates of overall and sustained PCR responses were low, suggesting a potential discordance between viral replication and clinical course and the need for continued surveillance.

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

FB designed the study, analyzed patient-level data, contributed patients and wrote the manuscript draft. MN conducted and is responsible for all statistical analyses. FB, KB, MC, and FH wrote the 

Overview of Immune Response during SARS-CoV-2 Infection: Lessons from the Past

Dexamethasone in Hospitalized Patients with Covid-19

Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial

Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected during the 2020 Pandemic

An EUA for Casirivimab and Imdevimab for COVID-19

Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): a Randomized Controlled, Open-Label, Platform Trial

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Emergency Use Authorization (EUA) for Bamlanivimab 700mg IV Center for Drug Evaluation and Research (CDER) Review (2021)

Anti-SARS-CoV-2 Neutralizing Monoclonal Antibodies: Clinical Pipeline

Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19

Features of 20 133 UK Patients in Hospital with COVID-19 Using the ISARIC WHO Clinical Characterisation Protocol: Prospective Observational Cohort Study

Mortality Analysis of COVID-19 Infection in Chronic Kidney Disease, Haemodialysis and Renal Transplant Patients Compared With patients without Kidney Disease: a Nationwide Analysis from Turkey

Kidney Transplant Recipients Have a Higher Mortality Due

Disease Compared to the General Population

Covid-19 and Kidney Transplantation

Coronavirus Disease 2019 in Kidney Transplant Patients from a Large UK Transplant Center: Exploring Risk Factors for Disease Severity

Real-World Experience of Bamlanivimab for COVID_19: A Case-Control Study

Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-Organ Transplant Patients

TBase -an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients

Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak Related to a Nightclub

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

The Neutralizing Antibody, LY-CoV555, Protects against SARS-CoV-2 Infection in Nonhuman Primates

The Dual Function Monoclonal Antibodies

Demonstrate Potent In Vitro and In Vivo Activity against SARS-CoV-2 bioRxiv

Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift. bioRxiv preprint

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited

manuscript. WD, UW, LL, AK, and MD contributed patients. K-UE contributed patients and critically revised the manuscript. NS, TL and MS organized antibody supply and collected and analyzed virological data. All authors approved the final version of the manuscript. 

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.